Material change biocompatibility

Why Every Material Change Biocompatibility Assessment Matters for Medical Device Safety

Material change biocompatibility assessment is required whenever a medical device undergoes a change in raw materials, suppliers, or manufacturing processes — because even minor modifications can introduce new chemical risks to patients. Regulatory agencies, including the FDA and ISO standards bodies, mandate a documented biological evaluation any time such changes occur, regardless of how small the alteration appears.

Furthermore,

For engineers and quality teams at Materials Metric, this topic sits at the heart of device lifecycle management. A new resin grade, a reformulated adhesive, or a supplier-driven raw material substitution can all shift the chemical profile of a finished device. Consequently, the biocompatibility status established during original clearance or approval may no longer apply. That gap between old data and new chemistry is precisely where patient risk accumulates undetected.

Furthermore, regulators have grown increasingly sophisticated in identifying inadequate change-control documentation. Submissions that rely on legacy biocompatibility data without addressing material changes frequently receive deficiency letters. Understanding when a material change triggers a full re-evaluation — and what testing that re-evaluation demands — is therefore one of the most practical compliance skills a device team can develop.

Key Takeaways

Any change to a device’s material composition, supplier, or processing method can trigger a new biocompatibility evaluation under ISO 10993 and FDA guidance.

Chemical characterization is the foundation of a material change biocompatibility assessment and can often replace or reduce animal testing.

Risk-based evaluation — not automatic full re-testing — is the correct regulatory framework for material changes.

Extractables and leachables data, toxicological risk assessment (TRA), and comparison to existing biological data all play roles in the evaluation strategy.

Documented justification for why certain endpoints were or were not tested is as important as the test results themselves.

Early engagement with a qualified laboratory reduces submission timelines and prevents costly deficiencies.

Material change biocompatibility: the structured process of evaluating whether a modification to a medical device’s material composition, supplier, or manufacturing method introduces new chemical, toxicological, or biological risks that could harm patients or users.

Key fact: Material or manufacturing changes are among the most common triggers cited in FDA biocompatibility-related deficiency letters for 510(k) and PMA submissions — making change-control documentation a leading compliance priority for device manufacturers.

What Counts as a Material Change for Biocompatibility Purposes?

Not every design update rises to the level of a biocompatibility-relevant material change. However, a surprisingly wide range of modifications can alter the chemical profile of a device. Understanding the scope of what regulators consider a “material change” is therefore the first practical step in any change-control program.

Regulatory guidance draws a distinction between changes that affect form or dimensions and changes that affect chemistry. Specifically, alterations in polymer grade, colorant, plasticizer, stabilizer, lubricant, adhesive, or coating all qualify as material changes. Moreover, a shift in resin lot-to-lot additive composition — even within the same trade name — can change extractable chemistry enough to warrant re-evaluation.

Changes That Directly Affect Chemical Composition

Direct compositional changes are the clearest triggers. For example, switching from one ISO 10993-certified silicone to a different supplier’s silicone product introduces unknown additive and catalyst residue profiles. Similarly, replacing a polyurethane grade with a chemically comparable alternative still requires verification that the new material’s leachable profile matches or improves upon the original.

In addition, changes to colorants, fillers, and processing aids deserve close attention. These components are present in small quantities but can produce biologically active leachables. Consequently, even an apparently cosmetic change — such as a new pigment for device color-coding — may require extractables testing and toxicological review before implementation.

Supplier and Manufacturing Process Changes

Supplier changes are among the most underestimated triggers in change control. A new supplier may use different polymerization catalysts, different stabilizer packages, or different purification steps — all of which affect residual chemistry. Therefore, “same specification, different vendor” is not a valid basis for assuming unchanged biocompatibility.

Manufacturing process changes also carry risk. Alterations to sterilization method, molding temperature, surface treatment, or cleaning chemistry can all modify the extractable profile of the finished device. For instance, switching from ethylene oxide to gamma irradiation sterilization can degrade certain polymers, generating new radiolytic byproducts. Notably, the ISO 10993-18 Chemical Characterization standard explicitly addresses the need to evaluate process-related changes alongside material-related ones.

Formulation Changes in Combination Devices

Combination devices — those that incorporate a drug, biologic, or diagnostic component — face an added layer of complexity. Specifically, changes to the drug formulation or delivery matrix can interact with the device material, producing new leachable species. Furthermore, container-closure and drug-device interface chemistries must both be re-evaluated when either component changes.

Overall, the key principle is broad rather than narrow: if a change could plausibly alter what the device deposits into the patient contact environment, it warrants at minimum a documented risk assessment. This principle underpins every major regulatory framework governing material change biocompatibility.

The Regulatory Framework Governing Material Change Biocompatibility

Two parallel frameworks govern material change biocompatibility assessments: the ISO 10993 series and FDA guidance documents. Together, they establish both the scientific methodology and the documentation expectations regulators apply during submission review. Understanding both is essential for building a defensible evaluation strategy.

ISO 10993 Series: The Scientific Standard

The ISO 10993 series provides the foundational scientific methodology for biological evaluation of medical devices. Part 1 of the series establishes a risk-based framework and a list of biological endpoints — cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation, and others — that must be considered for any device based on its nature of contact and duration of use.

Importantly, ISO 10993-18 specifically governs chemical characterization, which is the analytical cornerstone of any material change biocompatibility assessment. It establishes how to conduct extractables and leachables studies, how to calculate analytical evaluation thresholds (AETs), and how to interpret chemical data within a toxicological risk assessment. Furthermore, the standard explicitly supports the use of chemical characterization to justify waiving certain biological endpoint tests when the chemical data is sufficiently robust.

For related reading on how chemical characterization relates to the broader biocompatibility picture, see our article on chemical characterization vs. biocompatibility.

FDA Guidance: Use of ISO 10993-1 and the 2016 Blue Book Memo

The FDA’s 2016 guidance, “Use of International Standard ISO 10993-1: Biological Evaluation of Medical Devices,” clarified the agency’s expectations for how manufacturers should apply the ISO 10993 framework in submissions. Notably, the FDA emphasized that chemical characterization combined with a rigorous toxicological risk assessment (TRA) can often replace traditional in vivo endpoint testing. This shift has made analytical chemistry central to regulatory strategy.

Moreover, the FDA guidance addressed material changes directly. It states that whenever a device undergoes a material or process change, the manufacturer must revisit the biological evaluation plan (BEP) and determine whether existing data still supports biocompatibility or whether new testing is needed. Consequently, change-control procedures that lack a biocompatibility impact assessment step are considered deficient by reviewers.

For a deeper look at what FDA reviewers commonly flag in submissions, our article on FDA biocompatibility deficiencies covers the most frequent documentation gaps in detail.

Comparison of ISO 10993-1 and FDA Guidance Expectations

Requirement Area	ISO 10993-1	FDA 2016 Guidance
Biological Evaluation Plan (BEP)	Required for initial evaluation and changes	Must be submitted with the device submission
Chemical Characterization	Addressed under ISO 10993-18	Strongly preferred over in vivo testing where feasible
Toxicological Risk Assessment	Required to interpret chemical data	Must accompany chemical characterization data
Material Change Triggers	Composition, supplier, process, sterilization	Same categories; expects documented impact assessment
Endpoint Testing Waiver	Allowed with chemical and biological justification	Allowed; justification must be explicitly documented

How to Conduct a Risk-Based Material Change Biocompatibility Evaluation

A risk-based approach does not mean doing less work — it means doing the right work. Specifically, it means anchoring every decision in documented evidence about the chemical nature and magnitude of the change, the patient contact scenario, and the toxicological significance of any new or altered extractables. This structured methodology is what distinguishes a defensible evaluation from a gap-filled one.

Step 1 — Document the Change and Assess Its Chemical Scope

Every evaluation begins with precise characterization of what changed. This step requires obtaining material safety data sheets, certificates of analysis, and compositional disclosures from the supplier for both the original and new materials. Additionally, comparing these documents side by side often reveals additive differences, stabilizer changes, or residual monomer variations that are not obvious from trade names or product codes alone.

Next, teams assess whether the change is compositionally equivalent, similar, or substantially different. Equivalency determinations require chemical data, not just supplier declarations. Therefore, Chemical & Analytical Testing forms the first practical workstream in any rigorous material change evaluation. This data anchors the entire downstream risk assessment.

Step 2 — Perform Chemical Characterization and Extractables Testing

Chemical characterization involves systematically identifying and quantifying the chemical species that can migrate from the device under physiologically relevant conditions. This work follows ISO 10993-18 Chemical Characterization methodology, which defines extraction conditions, solvent selection, and analytical detection requirements based on the device’s intended contact conditions.

For organic extractables, GC-MS Analysis and HPLC Analysis are the workhorses of identification and quantification. Meanwhile, elemental impurities — including heavy metals — require techniques such as XRF Analysis and ICP-MS to meet the detection limits required by USP General Chapter <232> Elemental Impurities.

Surface chemistry changes from coatings or treatments benefit from XPS Analysis or FTIR Analysis, which reveal functional group changes and surface composition shifts invisible to bulk methods. In addition, structural confirmation of polymer identity after a supplier change can rely on Raman Spectroscopy or NMR Spectroscopy.

Step 3 — Compare New Chemical Data Against Existing Biocompatibility Records

Once analytical data is available, teams compare the new extractable profile to the original material’s known chemistry and existing biological test data. Specifically, reviewers look for new chemical species that were absent in the original device, increases in concentration of previously identified compounds, and the appearance of compounds with known toxicological concern.

If the new profile is a strict subset of the original — meaning no new compounds and no higher concentrations — the existing biocompatibility data may remain valid with a documented justification. However, if new compounds appear or concentrations increase above AET values, a toxicological risk assessment and potentially new biological endpoint testing become necessary. This comparison step is where a sound risk-based biocompatibility testing strategy delivers the most regulatory value.

Quick note: Regulators do not expect manufacturers to repeat all original biocompatibility tests after every material change. Instead, they expect a documented, science-based justification for which endpoints need re-evaluation and which existing data remains applicable. A well-structured chemical characterization package is often the most efficient path to that justification.

Analytical Tools Commonly Used in Material Change Biocompatibility Assessments

GC-MS: Identifies and quantifies volatile and semi-volatile organic extractables; primary tool for polymer additive profiling.
HPLC: Detects non-volatile organics including UV-absorbing compounds, antioxidants, and plasticizers.
ICP-MS / XRF: Quantifies elemental impurities including toxic heavy metals per USP <232> and ICH Q3D.
FTIR: Confirms polymer identity and detects surface chemical changes from coatings or treatments.
XPS: Characterizes surface elemental composition and bonding states at nanometer depth resolution.
NMR: Provides structural confirmation of polymer backbone and additive identity.
DSC: Detects thermal property shifts that indicate changes in polymer crystallinity or additive content via DSC Testing.
SEM/EDS: Reveals surface morphology and elemental distribution changes through SEM Analysis.

Together, these techniques form a comprehensive analytical toolkit for material change biocompatibility evaluation. Furthermore, selecting the right combination depends on the nature of the changed material, the device’s contact scenario, and the specific chemical concerns identified during the initial scoping review. Our Biocompatibility & Toxicity Testing team can help design an analytically appropriate and regulatorily defensible study plan tailored to the specific change under evaluation.

Toxicological Risk Assessment After a Material Change

Chemical characterization data alone does not complete a material change biocompatibility evaluation. Furthermore, every identified extractable must be assessed toxicologically to determine whether its concentration in the patient contact environment poses an acceptable risk. This step — the toxicological risk assessment (TRA) — is where chemical data translates into a regulatory decision.

How a TRA Evaluates Extracted Compounds

A qualified toxicologist reviews each identified compound against established safety thresholds. Specifically, they compare the estimated patient daily exposure (PDE) for each chemical to tolerable intake (TI) values derived from published literature, ICH Q3D, and USP Elemental Impurities guidance. Compounds with exposures well below their TI values typically require no further biological testing.

By contrast, compounds that exceed threshold values — or that lack adequate toxicological data — trigger the need for additional endpoint testing or a conservative safety justification. Consequently, the quality of the chemical data feeding into the TRA directly determines how efficient the overall evaluation becomes. Poorly quantified extractables data creates ambiguity that reviewers rarely accept without follow-up.

Thresholds and Decision Points

The analytical evaluation threshold (AET) is the key decision boundary in any ISO 10993-18-compliant study. Compounds detected above the AET must be identified and quantified; those below it need not be carried forward into the TRA. This threshold is calculated from the device’s patient exposure scenario, contact duration, and intended contact area.

Moreover, the threshold of toxicological concern (TTC) provides a secondary safety net for compounds that cannot be fully characterized. For structurally benign compounds detected near the AET, the TTC often supports a conclusion of acceptable risk without requiring dedicated biological testing. However, compounds with genotoxic alerts or known sensitization potential receive no benefit from TTC arguments and must be individually assessed.

Quick note: A toxicological risk assessment is not a generic document. It must be tailored to the specific changed material, the device’s contact category, and the patient population. Generic TRAs that ignore device-specific exposure scenarios are a common deficiency flag during FDA review.

Connecting TRA Outputs to Biological Endpoint Decisions

When TRA results support acceptable risk, manufacturers can document a justified waiver for biological endpoint tests that would otherwise apply. This justification must explicitly link the chemical data to each waived endpoint. For example, a genotoxicity study may be waived if no compounds with genotoxic structural alerts appear above the AET in the new material.

However, when TRA results raise concern, targeted biological testing becomes necessary. In those cases, our Biocompatibility & Toxicity Testing team can design endpoint-specific studies that address only the identified gap — rather than repeating the full original test matrix. This targeted approach saves time and resources while satisfying regulatory expectations.

Material Equivalency and Leveraging Existing Data

One of the most efficient strategies in material change biocompatibility management is demonstrating equivalency between the new and original material. Specifically, equivalency arguments allow manufacturers to leverage existing biological data rather than generate entirely new test packages. However, equivalency must be demonstrated through analytical evidence — not assumed from supplier declarations.

What Equivalency Requires Analytically

Demonstrating equivalency requires a side-by-side chemical characterization of both the original and new materials under identical extraction conditions. The new material must produce an extractable profile that contains no new compounds above the AET and no higher concentrations of previously identified compounds. Additionally, physical and thermal properties — confirmed by DSC Testing and FTIR Analysis — should confirm that the polymer structure itself has not changed.

For a comprehensive discussion of how equivalency arguments are structured within a regulatory submission, our article on device material equivalency provides detailed practical guidance. Furthermore, our Chemical & Elemental Characterization service supports the side-by-side analytical work that equivalency arguments demand.

When Equivalency Cannot Be Established

Sometimes the new material genuinely differs in chemical profile. In those cases, equivalency arguments are not appropriate — and attempting to force one creates significant regulatory risk. Instead, manufacturers must follow the risk-based path: conduct a full extractables study on the new material, perform a TRA, and determine which biological endpoints require new data.

Importantly, this outcome is not a failure. It is the correct scientific response to a genuine material difference. Regulators reward transparent, data-driven justifications far more than equivalency claims that lack supporting chemistry. Therefore, the willingness to conclude non-equivalency and proceed with targeted testing reflects scientific integrity and strengthens the overall submission.

Industry-Specific Considerations for Material Change Biocompatibility

Material change biocompatibility principles apply broadly across device categories. However, each product type carries unique contact scenarios, regulatory pathways, and risk profiles that shape how the evaluation is structured. Understanding these sector-specific nuances helps teams build more efficient and targeted evaluation strategies.

Implantable and Long-Term Contact Devices

Implantable devices represent the highest-risk category for material change biocompatibility evaluation. Specifically, ISO 10993-1 requires evaluation of the full endpoint matrix — including chronic toxicity, carcinogenicity, and implantation — for devices with prolonged internal tissue contact. Consequently, any material change in an implantable device demands exceptionally rigorous chemical characterization and TRA before biological testing is considered waived.

Furthermore, surface chemistry changes in implantables warrant particular attention. Techniques such as XPS Analysis and SEM Analysis reveal surface compositional and morphological changes that bulk extraction methods may miss entirely. These surface data often prove decisive in TRA and endpoint waiver justifications for long-term implants.

Drug-Device Combination Products and Container Closures

Combination products face dual regulatory oversight from both device and pharmaceutical frameworks. A material change in the device component must satisfy ISO 10993-18, while the impact on drug product quality and stability must also be addressed. Moreover, leachables from the device component that contact the drug formulation may accelerate degradation or introduce new impurities into the administered dose.

Extractables and leachables studies for combination products therefore require coordination between device biocompatibility data and pharmaceutical impurity analysis under ICH Q3B and related guidance. Our Chemical & Analytical Testing capabilities span both domains, supporting integrated E&L study designs that satisfy both regulatory frameworks simultaneously.

Single-Use and Externally Communicating Devices

Single-use devices — catheters, tubing, surgical instruments — have shorter contact durations, which generally reduces the tolerable intake thresholds applied in the TRA. Nevertheless, material changes in these products still require documented evaluation. By contrast, external communicating devices that contact blood or breached surfaces carry higher risk weights than intact-skin-contact items, and their evaluation must reflect that distinction.

Additionally, sterilization method changes in single-use devices are a particularly active area of material change biocompatibility review. For instance, many manufacturers are transitioning away from ethylene oxide sterilization, and those transitions require new extractables data to confirm that alternative sterilization methods do not generate unexpected degradation products from the device materials.

Quality Assurance and Documentation Best Practices

Strong analytical data and a sound TRA are necessary — but not sufficient — for a compliant material change biocompatibility submission. Equally important is the documentation framework that ties the chemistry, toxicology, and biological endpoint decisions together into a coherent, auditable record. Regulators evaluate the quality of the justification as closely as the quality of the data itself.

Building a Defensible Biological Evaluation Plan for Changes

Every material change biocompatibility evaluation should begin with an updated biological evaluation plan (BEP). This document maps the changed material to the device’s contact category, identifies the relevant biological endpoints under ISO 10993-1, and specifies which endpoints will be addressed through new testing, existing data, or documented waiver. Furthermore, the BEP should explicitly state the risk-based rationale for each decision.

An updated BEP is not optional for significant material changes — FDA guidance states that the BEP must reflect the current material configuration of the device. Our Scientific & Technical Consulting team routinely helps manufacturers draft and update BEPs that align with current regulatory expectations and withstand submission scrutiny.

Method Development and Validation for New Materials

When a new material has an unusual chemical profile — or when standard extraction methods do not adequately recover known compounds — custom analytical method development becomes necessary. Our Method Development & Validation service ensures that the extraction and detection methods used in a material change evaluation are fit for purpose, well-characterized, and documented to regulatory standards.

Specifically, method validation for extractables work typically includes demonstration of specificity, linearity, accuracy, precision, and detection limits appropriate to the AET. Published methodology from ScienceDirect and regulatory guidance documents provide the scientific framework that validated methods should reference. Consequently, validated methods provide a far stronger foundation for TRA conclusions than unvalidated screening approaches.

Change Control Integration and Ongoing Monitoring

Material change biocompatibility evaluation should not be a one-time reactive exercise. Rather, it functions best when integrated into a manufacturer’s formal change control system from the outset. Specifically, every change request should trigger a biocompatibility impact assessment — a documented review that determines whether the change is biocompatibility-relevant before any implementation decision is made.

Moreover, ongoing supplier monitoring helps detect drift in incoming material chemistry before it creates a compliance gap. Periodic Chemical Purity & Contaminant Screening of incoming raw materials provides early warning of lot-to-lot variability that could affect the device’s established biocompatibility profile. This proactive approach prevents the costly scenario of discovering a biocompatibility gap only after a product is already in the field.

Comparison: Reactive vs. Proactive Change Control Approaches

Factor	Reactive Approach	Proactive Approach
Trigger point	Deficiency letter or audit finding	Change request initiation
Testing timeline	Compressed, under regulatory pressure	Planned and adequately resourced
Documentation quality	Often retrospective and incomplete	Contemporaneous and auditable
Regulatory outcome	Higher risk of hold or rejection	Faster review with fewer questions
Cost profile	Higher total cost due to rework	Lower total cost; targeted testing only

Frequently Asked Questions About Material Changes and Biocompatibility

Does every material change require new biocompatibility testing?

No — but every material change requires a documented impact assessment. Specifically, manufacturers must evaluate whether the change alters the chemical profile of the device in a way that affects the validity of existing biocompatibility data. If chemical characterization confirms that the new material’s extractable profile is equivalent to or more favorable than the original, existing biological data may remain applicable with a documented justification. New biological testing is required only when the TRA identifies gaps that existing data cannot address.

What is the difference between extractables and leachables in this context?

Extractables are chemical species removed from a material under aggressive laboratory extraction conditions — typically using exaggerated solvents or temperatures. Leachables, by contrast, are the subset of compounds that actually migrate from the device under normal clinical use conditions. Furthermore, extractables studies define the worst-case chemical universe; leachables studies confirm actual patient exposure. Both are relevant to material change biocompatibility evaluation, with the study design depending on the device’s contact scenario and the nature of the change.

How does a supplier change trigger biocompatibility re-evaluation?

A supplier change can introduce differences in polymerization catalysts, additive packages, stabilizers, or purification methods — even when the material meets the same functional specification. Consequently, the extractable chemistry of the nominally identical material may differ between suppliers. Therefore, regulatory guidance treats supplier changes as potential material changes and requires at minimum a chemical comparison study. Our Chemical & Elemental Characterization service directly supports this comparison work.

How long does a material change biocompatibility evaluation typically take?

Timeline varies significantly based on the complexity of the change and the analytical methods required. A focused chemical characterization study with a straightforward TRA may conclude in six to ten weeks. However, cases requiring new biological endpoint testing — particularly subchronic toxicity or implantation studies — can extend the timeline to six months or more. Therefore, early engagement with a qualified laboratory during the change planning phase is the most effective way to manage timeline risk.

Can chemical characterization alone satisfy the biocompatibility requirement after a material change?

In many cases, yes. The FDA and ISO 10993-18 both recognize that robust chemical characterization combined with a qualified TRA can support the waiver of specific biological endpoint tests. However, this approach requires that the chemical data be analytically complete, the TRA be performed by a qualified toxicologist, and the justifications for each waived endpoint be explicitly documented. Incomplete chemical packages or generic TRAs rarely survive regulatory scrutiny without follow-up questions.

What documentation should a manufacturer retain after completing a material change evaluation?

Manufacturers should retain the complete analytical data package, TRA report, updated BEP, equivalency comparison (if applicable), any new biological test reports, and the final biocompatibility evaluation report (BER) that integrates all findings into a regulatory conclusion. Additionally, the change control record itself should reference the BER and document the decision basis for each endpoint. Our Wet Chemistry & Classical Analytical Methods and broader analytical services generate study reports formatted to meet these documentation requirements directly.

Conclusion

Material change biocompatibility evaluation is one of the most consequential compliance activities in medical device lifecycle management. Furthermore, it is also one of the most frequently mishandled — either because the scope of “material change” is underestimated, or because the evaluation relies on outdated data without proper analytical justification. Both errors carry real regulatory and patient safety consequences.

The good news is that a well-structured, risk-based approach — anchored in rigorous chemical characterization and a qualified TRA — provides a clear and efficient path through every material change scenario. Specifically, manufacturers who invest in quality analytical data early in the change process consistently achieve faster regulatory review, fewer deficiency letters, and stronger long-term compliance posture.

Moreover, no material change evaluation needs to be navigated alone. From extractables and leachables testing to method validation, toxicological risk assessment support, and biological evaluation plan development, Materials Metric provides the full analytical and scientific infrastructure that device teams need. In addition, our consultants bring deep regulatory familiarity with ISO 10993-18, FDA guidance, and the practical documentation standards that submissions require.

Whether you are managing a straightforward supplier change or a complex reformulation across a combination product platform, we are ready to help. To discuss your specific material change scenario and get a tailored evaluation plan, contact Materials Metric today — and ensure your biocompatibility documentation is built on the analytical foundation it needs to succeed.